John Maraganore (L) and Giuseppe Ciaramella

Watch out Mod­er­na: John Maraganore, ARCH and Beam are hatch­ing a plat­form play 'to lead the fu­ture of RNA ther­a­pies'

Giuseppe Cia­ramel­la joined Mod­er­na in 2014, back when the mR­NA spe­cial­ist on­ly em­ployed about 70 peo­ple. There, as CSO of the in­fec­tious dis­ease di­vi­sion, he helped build the ini­tial mR­NA vac­cine pipeline and steered Mod­er­na’s first vac­cine pro­gram to­ward an IND.

He left for Beam Ther­a­peu­tics four years lat­er, be­fore a wild­ly suc­cess­ful Covid-19 vac­cine pro­pelled Mod­er­na to the biotech hall of fame.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.